Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma-Reference-Cited by-同舟云学术

Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma

Published:2014-11-20 Issue:3 Volume:121 Page:557-563
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Taylor Jennie W.,Dietrich Jorg,Gerstner Elizabeth R.,Norden Andrew D.,Rinne Mikael L.,Cahill Daniel P.,Stemmer-Rachamimov Anat,Wen Patrick Y.,Betensky Rebecca A.,Giorgio Diana H.,Snodgrass Kellis,Randall Alison E.,Batchelor Tracy T.,Chi Andrew S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-014-1667-z.pdf

Reference28 articles.

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine 352:987–996. doi: 10.1056/NEJMoa043330

2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi: 10.1016/S1470-2045(09)70025-7

3. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. doi: 10.1200/JCO.2008.19.8721

4. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745. doi: 10.1200/JCO.2008.16.3055

5. Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG, Frame MC (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 4:632–638. doi: 10.1038/ncb829

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors;Computational Methods in Drug Discovery and Repurposing for Cancer Therapy;2023

2. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review;BMC Medical Research Methodology;2022-12-22

3. UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity;Cancers;2022-10-29

4. Evaluation of Two-stage designs of Phase 2 single-arm trials in glioblastoma: A systemic review;2022-09-08

5. Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future;Frontiers in Oncology;2022-06-17